-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Connec Biomedical (NASDAQ: CNTB) ("Connad" or the "Company") is a globally developed biopharmaceutical company with clinical-stage products that develops innovative therapies through its self-developed T cell function modulation platform to improve the quality
In this randomized, double-blind, placebo-controlled, single oral dose-escalation (SAD) trial, CBP-174 was observed to be safe and well tolerated in eight dose-escalating groups (up to a maximum dose of 16 mg or placebo), with no serious adverse events, and the reported adverse events were predominantly mild and no dose-limiting toxicity was
"This positive data from the first human clinical trial shows that CBP-174 is making good progress as a new treatment for pruritus associated with allergic and inflammatory skin diseases, including atopic dermatitis, which plague millions of people worldwide," said Dr.